Clinical Trials

40 enrolled

Triple Negative Breast Neoplasms

NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

35 enrolled

Triple Negative Breast Neoplasms

NCT05154396 2021-12-13

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

60 enrolled

HER2-positive Breast Cancer

NCT05020964 2021-08-25

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

68 enrolled

Advanced Breast Cancer

NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT03535961 2020-12-02

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

32 enrolled

Breast Neoplasms

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

26 enrolled

Breast Neoplasms

NCT03933319 2020-07-08

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

HER2-positive Breast Cancer

NCT03939871 2020-06-23

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Hormone Receptor Positive Advanced Breast Cancer

NCT04437160 2020-06-18

Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

Phase 2 Recruiting

286 enrolled

Triple Negative Breast Neoplasms

NCT04194684 2019-12-11

Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer

108 enrolled

Breast Neoplasms

NCT04033172 2019-07-25

Pyrotinib

40 enrolled

Breast Neoplasms

NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03923166 2019-04-22

Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer

35 enrolled

Breast Neoplasms

NCT03923179 2019-04-22

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

32 enrolled

Breast Neoplasms

NCT03854617 2019-02-26

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

172 enrolled

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT03735082 2018-11-08

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

29 enrolled

Breast Neoplasms

NCT02646735 2017-01-02

FRIEND

148 enrolled

Breast Neoplasms

NCT02947061 2016-10-31

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

300 enrolled

Breast Cancer Recurrent

NCT02934828 2016-10-18

Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

230 enrolled

Breast Neoplasms

NCT02829008 2016-07-12

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

120 enrolled

Breast Neoplasms

NCT01939054 2015-06-04

Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

90 enrolled

Breast Neoplasms

NCT02460744 2015-06-02

2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer

Phase 2 Completed

50 enrolled

Breast Neoplasms

NCT01928680 2015-02-23

Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer

33 enrolled 5 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02313051 2014-12-09

MIRACLE

200 enrolled

Breast Neoplasms

NCT02041338 2014-11-25

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

200 enrolled

Breast Neoplasms

NCT01492543 2013-03-15

Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer

Breast Neoplasms, Neoplasm Metastasis

NCT01492556 2013-03-15

Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer

100 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT01431053 2013-03-13

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

160 enrolled

Breast Neoplasms

NCT01276769 2011-11-16

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

80 enrolled